Sonic Incytes Appoints New CEO and Chair to Accelerate Growth
February 3, 2022
Following the closing of its US$7.3M Series A raise in December 2021, the Sonic Incytes Medical Corp. Board of Directors is pleased to announce the appointment of Barry Allen as the new CEO and Natalie Dakers as the new Board Chair to lead the company through its next stage of growth.
“Our focus is on building a strong foundation to build an even better company – one that creates greater value for our shareholders and customers. I’m excited about the opportunity to propel our company forward with our lead product VelacurTM, the first handheld 3D liver health assessment solution,” states Allen, who is a serial founder and operator with 30 years of executive management and board experience in the medtech, software and digital industries in both public and private companies.
Allen’s start-up experience includes Founder, Chair and CEO of Zolo, President & CEO of PureWeb Inc., Founder and CEO of VSM MedTech, Founder and CEO of Urodynamix. His community involvement includes Associate Creative Destruction Labs West and Rockies, Founder and Chair of the BC Excels Program, Entrepreneur in Residence at Ventures West, and lead mentor with BC Innovation Council. Allen has held a number of directorships in private and public companies and is currently the Chair and Director of Zolo and Orpyx Medical.
“This is an exciting turning point for the company. With strong support from our shareholders, we are well-positioned to take VelacurTM to the next level and strengthen our market penetration in the U.S.,” says Dakers, who brings extensive experience as a leading figure in the Canadian health sciences sector over the past 25 years.
Dakers has been the founding CEO of several high impact and first-of-its-kind organizations including Accel-Rx Health Sciences Accelerator, the Centre for Drug Research and Development (CDRD) now Admare BioInnovations, and CDRD Ventures. She co-founded Neuromed Pharmaceuticals, a venture-backed biotechnology company in the neurological space developing drugs for chronic pain and epilepsy.
Dakers currently serves on the Board of Directors of LifeLabs, Pender Private Investments, Sonic Incytes, Augurex, BioTalent Canada, and Stemcell Technologies. She is an Associate in the CDL Health Cohort in Vancouver and is an Adjunct Professor at UBC’s Faculty of Pharmaceutical Sciences.
About Sonic Incytes Medical Corp.
Sonic Incytes believes in creating accessible and affordable healthtech solutions – with health insights you can count on – to improve patient care. Recognizing the rise of chronic liver disease, Sonic Incytes is on a mission to make liver health a new vital sign. Its novel, point of care ultrasound solution, VelacurTM, is redefining the standard of care in quantifying liver tissue stiffness and attenuation to aid in the clinical management of patients with chronic liver disease.